These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 19335369)

  • 21. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linezolid for the treatment of drug-resistant infections.
    Herrmann DJ; Peppard WJ; Ledeboer NA; Theesfeld ML; Weigelt JA; Buechel BJ
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):825-48. PubMed ID: 19053895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens.
    Witte W; Cuny C; Klare I; Nübel U; Strommenger B; Werner G
    Int J Med Microbiol; 2008 Jul; 298(5-6):365-77. PubMed ID: 18325835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future treatment options for Gram-positive infections--looking ahead.
    Barton E; MacGowan A
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():17-25. PubMed ID: 19917023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence and management of drug-resistant enterococcal infections.
    Arias CA; Murray BE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):637-55. PubMed ID: 18847403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci.
    Leclercq R
    Clin Microbiol Infect; 2009 Mar; 15(3):224-31. PubMed ID: 19335370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of antibiotic-resistant Gram-positive pathogens.
    Lode HM
    Clin Microbiol Infect; 2009 Mar; 15(3):212-7. PubMed ID: 19335368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH; Kish TD; Fung HB
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
    Peppard WJ; Johnston CJ; Urmanski AM
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):83-99. PubMed ID: 18251666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment options for multidrug-resistant bacteria.
    Giamarellou H
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):601-18. PubMed ID: 17009940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN; Rybak MJ
    Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
    Arhin FF; Belley A; McKay GA; Moeck G
    Curr Protoc Microbiol; 2010 Feb; Chapter 17():Unit17.1. PubMed ID: 20131224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New treatments for multiply drug-resistant Gram-positive bacteria.
    Moellering RC
    J Infect; 2009 Sep; 59 Suppl 1():S1-3. PubMed ID: 19766884
    [No Abstract]   [Full Text] [Related]  

  • 37. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's new and not so new on the antimicrobial horizon?
    French GL
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():19-29. PubMed ID: 19040463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance mechanisms of gram-positive bacteria.
    Berger-Bächi B
    Int J Med Microbiol; 2002 Jun; 292(1):27-35. PubMed ID: 12139425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.